New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
10:58 EDTJNJEarnings Preview: Johnson & Johnson at five-year high ahead of Q4 report
Johnson & Johnson (JNJ) is scheduled to report Q4 results before the open on Tuesday January 22, with a conference call scheduled for 8:30 am ET. Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide... EXPECTATIONS: Analysts are looking for EPS of $1.17 on revenue of $17.67B, according to First Call. The consensus range for EPS is $1.13-$1.23 on revenue of $17.46B-$17.98B... LAST QUARTER: J&J reported Q3 EPS $1.25 against estimates of $1.21 on revenue of $17.1B against estimates of $16.95B. In its Q3 report, the company gave FY12 EPS guidance of $5.05-$5.10 compared to estimates of $5.06. J&J cited by Remicade, Prezista, Velcade as Q3 growth drivers but noted that Q3 sales were hurt by manufacturing suspension at Doxil/Caelyx supplier. During the Q3 earnings conference call CFO Dominic Caruso said U.S. healthcare utilization rates show early signs of stabilization and U.S. joint reconstruction volumes appear to have improved in the latest data but cautioned that although some positive signs can be seen, it is "still too early to signal any meaningful recovery"... STREET RESEARCH: In the last two months, analysts have been generally positive on J&J. On January 4, Deutsche Bank upgraded Johnson & Johnson to Buy from Hold, citing the company's diversification and expectations the company will see improving trends in 2013. The firm raised its price target for shares to $82 from $75. On December 10, Davenport upgraded the shares to Buy from Neutral with an $80 price target... PRICE ACTION: Shares of Johnson and Johnson are trading near a five-year high of ~$73. The shares rose from around $69 per share to $72.74 on Q3 earnings in October, and have since rallied approximately 5% to $72.94.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use